Feds charge ACT and ex-CEO for hiding stock sales
NeuroMetrix names new consumer GM | Personnel Moves
CareFusion updates on annual report | Wall Street Beat
CareFusion (NYSE:CFN) said it’s done with most of its review of the accounting for its Pyxis medication dispensing line, which delayed the filing of its 4th-quarter and annual reports and prompted a warning from the New York Stock Exchange.
St. Jude Medical rebounds after “Greek tragedy” | Wall Street Beat
Shares of St. Jude Medical (NYSE:STJ) clawed back some of the value lost yesterday in what 1 waggish analyst termed a “Greek tragedy.”
STJ shares closed down 3.3% yesterday at $39.96 when the company revealed a $56 million writedown after a Greek distributor failed to pay up for an estimated 2 years worth of sales.
BioMimetic slashes 25% of jobs following FDA delays | MassDevice.com On Call
MASSDEVICE ON CALL — BioMimetic Therapeutics (NSDQ:BMTI) cut 25% of its workers in hopes of saving some cash in focusing on getting FDA pre-market approval for its Augment bone graft.
The federal watchdog agency’s advisory panel recommended approving the treatment in May 2011, after releasing a dim summary of the pre-market approval application that sunk BMTI shares by more than 35%.
Sanovas expands in Calif. in prep for commercial launch | MassDevice.com On Call
MASSDEVICE ON CALL — Sanovas is expanding its corporate headquarters and opening a manufacturing facility in Sausalito, Calif. as it prepares to file for FDA clearance for its drug-delivery technology.
The company’s micro-surgical technologies feature what Sanovas calls the world’s smallest surgical camera to access hard-to-reach areas of the body and provide minimally invasive diagnosis, treatment and drug delivery, according to a press release.
Diabetes: WPI team gets $1.2M for diabetes care app | Funding Roundup
A research team from Worcester Polytechnic Institute won a $1.2 million grant from the National Science Foundation to develop a smart phone app for people with advanced diabetes.
The proposed application, currently named "sugar," will link a patient’s smart phone, glucose meter and scale to track and archive blood sugar levels and weight. Patients with foot ulcers will be able to use the phone’s camera to capture and analyze images of the lesions.
ACT appoints MIT big shot Langer to board | Personnel Moves
Advanced Cell Technology (OTC:ACTC) appointed MIT professor and bioengineering legend Bob Langer to its board of directors, tapping him to lead its science advisory committee.
Langer has authored more than 1,100 journal articles, has more than 800 issued and pending patents and won the 2011 Warren Alpert Foundation Prize for bioengineering pioneers thanks to his work in drug delivery and tissue engineering.
Dr. Robert Langer joins ACT’s Board of Directors
Scientific Luminary Dr. Robert Langer Joins ACT’s Board of Directors
World-renowned scientist and youngest member ever elected to all three U.S. National Academies; Also named One of the 100 Most Important People in America by Time Magazine and CNN
MARLBOROUGH, Mass. — Oct. 5, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Robert S. Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), has been appointed to the company’s Board of Directors, and will also serve as the Chair of the Board’s Science Advisory Committee.
BSX’s CEO, Bard’s bids for Clearstream, Infuse’s lawsuits , AdvCellTech’s stem cell trail, NuVasive’s spat, BSX’s narrow escape and Mako’s Wall Street love made headlines this week | MassDevice.com +7
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Advanced Cell Technology launches historic clinical trial
Advanced Cell Technology Inc. (OTC:ACTC) is set to begin Europe’s first study involving human embryonic stem cells, as it begins a trial to consider an experimental treatment for a form of juvenile blindness.
"This is the first time an embryonic stem cell trial has ever been approved anywhere else in the world [outside the U.S.]," chief scientific officer Dr. Robert Lanza said.
MassDevice Network
@MassDevice
LinkedIn
YouTube